News

EMA Accepts Conditional Application for ANCA Treatment Avacopan

The European Medicines Agency (EMA) has accepted for review ChemoCentryx’s application to approve Avacopan (CCX168) as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The company, with its partner Vifor Fresenius Medical Care Renal Pharma, applied for a Conditional Marketing Authorization (CMA) of the medicine. A CMA…

Rituxan Effective in Keeping ANCA Vasculitis at Bay, Saudi Study Shows

Rituxan (rituximab) effectively induces and maintains remission in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a new Saudi study shows. The study, “Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and…

Many ANCA-associated Vasculitis Patients with a Particular Antibody Have Bronchiectasis, Study Shows

Many ANCA-associated vasculitis patients who have a certain type of autoantibody develop the widened-airway condition known as bronchiectasis, a French study shows. The question of whether the respiratory tract is the place where ANCA-associated vasculitis develops remains to be seen, however, the researchers said. The hallmark of ANCA-associated vasculitis is…

GSK’s Nucala Approved by FDA as Add-on Therapy for EGPA Patients

The U.S. Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on to standard care for treating eosinophilic granulomatosis with polyangiitis (EGPA), previously called Churg-Strauss syndrome. “Patients suffering from EGPA too often face a frustrating journey from a delay in receiving a proper diagnosis to having…

Adding Azathioprine to Glucocorticoid Regimen Doesn’t Improve SNV Remission Rates, Study Finds

The addition of azathioprine, an immunosuppressant, to a glucocorticoid treatment regimen does not improve remission rates for patients with non-severe systemic necrotizing vasculitides (SNVs), a new study shows. The study, “Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without…